Ipsos MMA and HealthVerity partner to reinvent omnichannel patient and HCP attribution in the pharma industry
APRIL 27, 2022 — 08:30 AM EDT
Ipsos MMA brings a new approach to measuring the impact of commercial investments across the patient and physician journey to maximize the value of campaigns for Pharma brands and their agency partners.
NEW YORK, NY — (PRNewswire) — Ipsos MMA, a leader in helping pharma and healthcare brands measure and optimize the value of their patient and HCP promotions, today announced a partnership that integrates Ipsos MMA’s Unified Patient & HCP Attribution model with HealthVerity IPGE, the industry’s leading infrastructure for patient identity resolution, privacy, governance and exchange of broadscale healthcare and consumer data. The partnership delivers privacy-protected and HIPAA-compliant activations with media platforms for pharmaceutical brands as an end-to-end, closed-loop measurement and optimization solution.
This innovative and future-proofed capability enables pharmaceutical marketers to generate and activate audiences, measure the quality of the audiences reached and optimize omnichannel net conversion lift while campaigns are in market. Through a combination of privacy-protected, HIPAA-compliant data, processes and advanced AI modeling, brands can now automate “next best actions” across patient and physician journeys to drive incremental scripts and adherence, maximizing long-term profits.
Ipsos MMA’s Unified Patient & HCP Attribution model has been validated with clients and has been shown to produce measurable improvements in revenue and profits. Ipsos MMA has also been named a leader in The Forrester Wave™ : Marketing Measurement & Optimization Solutions, Q1 2022.
“We have partnered with some of the top pharma brands, their agencies, HealthVerity and industry data partners/platforms across the media ecosystem to validate that our integrated solutions will produce better results for our clients. We believe that by working closely with them to operationalize these capabilities it will prove to provide transformational results for the industry,” said Doug Brooks, EVP at Ipsos MMA. “Ipsos MMA’s Unified Patient & HCP Attribution capability unlocks the omnichannel opportunity for pharma executives by taking advantage of synergies between DTC, HCP and sales force, enabling orchestrated planning, optimizing campaigns in-market, targeting and creating new audiences and leveraging both Patient and Physician journeys for Next Best Action through an innovative use of AI.”
“With this capability, pharma brands can integrate patient and HCP marketing journeys and enhanced data attributes to generate, activate, and prioritize high-value audiences that are linked to downstream conversions while campaigns are live. Our unique solution does not rely on third-party cookies and is not impacted by advancements in data deprecation. This approach gives brand and media planners true cross-platform and omnichannel investment optimization opportunities. In a world where data privacy is critical, we can offer marketers and their agencies a safe way to activate and measure both traditional and digital channels against intended audiences,” said Robert Cardarelli, EVP Analytics and Attribution for Ipsos MMA.
What is the benefit of this approach to Pharmaceutical Marketers?
Holistic Measurement and Campaign Management
Omnichannel impact of Patient and Physician journeys to increase patient visitation, NBRx and adherence
Optimize campaigns across audiences, targeting tactics, partners, creative measures and reach & frequency – while in-flight
Identify which Next Best Actions need to be taken across both Patient and Physician journeys to drive maximum conversion lift and ROI
Campaign Performance Management
Ensure optimal audience quality and cost per qualified audience while meeting targeting benchmarks and downstream end actions
Interoperable Data Ecosystem
With over 150 billion de-identified transactions from more than 75 unique data sources and 330 million patients, HealthVerity provides access to the largest healthcare and consumer data ecosystem available in the market today.
HIPAA-Compliant Data Clean Rooms
Securely brings together data with a HIPAA-compliant data clean room for audience selection and media measurement for back-end analytics from HealthVerity. The complete solution enables a full closed-loop process to help target and optimize campaigns while ensuring clients get the desired outcomes.
Learn more about Ipsos MMA’s Unified Patient/HCP Attribution capability.
View the full release here: https://www.prnewswire.com/news-releases/ipsos-mma-and-healthverity-partner-to-reinvent-omnichannel-patient-and-hcp-attribution-in-the-pharma-industry-301534210.html
About Ipsos MMA
Ipsos MMA is a leading global analytics consultancy founded in 1989. The company enables its clients to achieve higher revenues and operating profits via their forward-looking, data-driven analytics, software and consulting solutions. Ipsos MMA is headquartered in New York, NY and is a part of the leading global custom market research company Ipsos, which has major offices in over 80 locations worldwide. To learn more about Ipsos MMA, visit mma.com.
Pharmaceutical manufacturers, payers and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance and Exchange, enables the discovery of RWD across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about out how HealthVerity and Ipsos MMA work together visit our Partners Page.
Request Demo or More Information
It’s time to Synchronize the Science℠
Complete the form to explore how synchronizing transformational technologies with the nation’s largest real-world data ecosystem can fundamentally advance the science.